In the name and on behalf of FIL Limited, Pembroke Hall, 42 Crow Lane, Pembroke, HM19 Bermuda, (the “Investment Manager”) we hereby notify you pursuant to STA Chapter 4, Section 4-1 the following:
On 19 January 2021 the shares and rights to shares in Ultimovacs ASA (the “Company”) attributable to the Investment Manager crossed above the threshold of 5%.
The threshold was crossed by means of a Purchase of 6,332 shares.
Therefore, the total shareholding deemed to be held is 1,601,941 which represent 5.01% of the shares outstanding and voting rights of the Company.
The shares and rights to shares are owned by the funds listed on Schedule A and are managed by the designated management companies which are undertakings controlled by the Investment Manager.
If you have any questions with respect to this notification, please contact Paul Clark, Regulatory Reporting Manager, at +353 1 223 1447 or via email fil-regreporting@fil.com.
See attachment on www.newsweb.no